Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?
Fischer
Peter M
PM
Cyclacel Limited, James Lindsay Place, Dundee DD1 5JJ, Scotland, UK. pfischer@cyclacel.com
Lane
David P
DP
D000818:Animals; D001665:Binding Sites / Q000187:drug effects / Q000502:physiology; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism* / Q000502:physiology; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism* / Q000502:physiology; D051736:Proto-Oncogene Proteins c-mdm2; D012097:Repressor Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors* / Q000378:metabolism*
D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D012097:Repressor Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2